Stockscreener 앱 받기
29.10
10.19%
2.69
시간 외 거래:
29.06
-0.04
-0.14%
Arcutis Biotherapeutics Inc 주식(ARQT)의 최신 뉴스
Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical - GlobeNewswire Inc.
An iShares ETF has an interest above 5% in Arcutis (ARQT), where BlackRock reports a passive stake. - Stock Titan
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.
Arcutis Biotherapeutics, Inc. (ARQT) Stock Price, News, Quote & History - Yahoo! Finance Canada
Merck's Tulisokibart Meets Endpoints in Hidradenitis Suppurativa Study - Zacks Investment Research
Arcutis Biotherapeutics EVP Matsuda sells $91.8k in shares - Investing.com
Arcutis Biotherapeutics director Welgus sells $114k in shares By Investing.com - Investing.com India
Here’s What Arcutis’ CEO Said at the Morgan Stanley Healthcare Conference That Made the Stock Jump 11% - TIKR.com
Arcutis Biotherapeutics director Welgus sells $114k in shares - Investing.com
Former Arcutis (NASDAQ: ARQT) officer plans multimillion-dollar stock sale - Stock Titan
Arcutis Biotherapeutics (NASDAQ: ARQT) director plans $114K stock sale - Stock Titan
Arcutis EVP, Chief Legal Officer Masaru Matsuda sells 9,989 shares for $249,861 - Bitget
Arcutis Biotherapeutics (ARQT) Insider Masaru Matsuda Sells 9,98 - GuruFocus
Arcutis Biotherapeutics EVP Masaru Matsuda sells $249,985 stock - investing.com
Arcutis Biotherapeutics EVP Masaru Matsuda sells $249,985 stock By Investing.com - Investing.com Canada
Arcutis Biotherapeutics EVP Masaru Matsuda sells $249,985 stock - Investing.com
Arcutis (ARQT) officer lines up Rule 144 stock sale - Stock Titan
Arcutis Biotherapeutics (NASDAQ:ARQT) Delivers High Growth with Improving Fundamentals - ChartMill
Atopic Dermatitis Drugs Market Set to Reach USD 33.42 Billion by 2035, at a CAGR of 7.70%SNS Insider - GlobeNewswire Inc.
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - manilatimes.net
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.
(ARQT) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Arcutis Management to Present at the Morgan Stanley 24th Annual Global Healthcare Conference - manilatimes.net
Arcutis Management to Present at the Morgan Stanley 24th Annual Global Healthcare Conference - Barchart.com
ARQT Stock Price, Quote & News - Syfe
Arcutis director Terrie Curran sells $956k in shares By Investing.com - Investing.com Nigeria
Arcutis director Terrie Curran sells $956k in shares By Investing.com - Investing.com Canada
Arcutis director Terrie Curran sells $956k in shares - Investing.com
Here's Why You Should Add ARQT Stock to Your Portfolio Now - theglobeandmail.com
Here's Why You Should Add ARQT Stock to Your Portfolio Now - TradingView
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen - Yahoo Finance
Arcutis (NASDAQ: ARQT) insider plans $956K share sale - Stock Titan
Insider Decision Unfolding At Arcutis Biotherapeutics: Terrie Curran Exercises Options, Resulting In $18K - benzinga.com
Arcutis Biotherapeutics Director Terrie Curran Executes Stock Option and Sells Shares on August 20, 2026 - Kalkine Media
Arcutis Biotherapeutics CMO Patrick Burnett Sells Shares to Cover Tax Withholding on RSU Vesting - Kalkine Media
Tejara Capital Ltd Buys Shares of 113,084 Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Polar Capital Holdings Plc Buys Arcutis Biotherapeutics Inc (ARQ - GuruFocus
Arcutis (NASDAQ: ARQT) director to sell 1,072 shares - Stock Titan
ARQT Looks 18.5% Undervalued on GF Value™ After Health Canada Ap - GuruFocus
PrZORYVE® Cream 0.05% Receives Health Canada Approval for Children Aged 2 to 5 Years with Mild to Moderate Atopic Dermatitis - PR Newswire Canada
Arcutis Biotherapeutics (NASDAQ:ARQT) Director Howard Welgus Sells 4,730 Shares - MarketBeat
Arcutis (NASDAQ: ARQT) officer to sell 1,697 shares after recent August trades - Stock Titan
Arcutis Biotherapeutics (NASDAQ:ARQT) Pairs High Growth Momentum with a Breakout Setup - ChartMill
Arcutis (ARQT) Q2 2026 Earnings: EPS Beats Its Estimate in Latest Trading; Shares After the Report: The Stock Ends Up 3.63% at the CloseSegment Revenue Breakdown - Vinanet
Arcutis (NASDAQ: ARQT) holder plans $123,834 August sale - Stock Titan
Arcutis (ARQT) Q2 2026 Earnings Call Transcript - AOL.com
Arcutis Biotherapeutics (ARQT) Gains 1.39% as Shares Push Toward Key ResistanceSupport Level Bounce - Vinanet
Should Arcutis Biotherapeutics’ (ARQT) Strong Q2 and Higher 2026 Sales Outlook Prompt Investor Action? - webull.com
Liquidity Mapping Around (ARQT) Price Events - Stock Traders Daily
0.75%
1.41%
자본화:
|
볼륨(24시간):